相关实验视频
Updated: Jan 15, 2026

10:45
Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
Published on: May 25, 2017
15.1K
肝脏基因组揭示了PS1145作为减轻酒精相关肝病系统性炎症的治疗剂
Manisha Yadav1, Abhishak Gupta2, Sanju Yadav1
1Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|January 13, 2026
概括
一种IKK-酸化抑制剂PS1145在与酒精有关的肝病 (ALD) 模型中有效降低了炎症和肝损伤. 它针对关键的炎症通路,在其他治疗方法不足的情况下显示出治疗前景.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 与酒精有关的肝病 (ALD) 缺乏有效的抗炎治疗方法.
- 激酶信号通路对于协调炎症反应至关重要.
- 基因组分析是一种合理的方法,用于识别ALD的新型治疗点.
研究的目的:
- 在慢性乙醇养的老鼠模型中分析肝脏和单细胞基因组变化.
- 确定治疗点,以减轻ALD的炎症.
- 在临床前的ALD模型中评估路径特异性抑制剂,包括PS1145.
主要方法:
- 长期以乙醇养大鼠的肝脏和单细胞中的基因组概况.
- 在ALD大鼠,患者PBMC和NIAAA小鼠模型中评估抑制剂 (PS1145,PH797804,白醇,普德尼索隆).
- 对炎症标志物,NFκB激活和TLR信号的分析.
主要成果:
- 基因组分析显示,ALD大鼠肝脏和单细胞激酶的显著改变.
- 观察到参与MyD88-TLR4,PI3K-Akt,TNF和MAPK14通路的激酶的升级.
- PS1145抑制了NFκB激活和炎症,优于其他测试的抑制剂,并在小鼠模型中改善了肝脏病理.
结论:
- PS1145有效地阻断IKK酸化和TLR二元化.
- 这种抑制减轻了炎症并改善了ALD肝脏病理.
- PS1145在治疗与酒精有关的肝病方面具有显著的治疗潜力.
相关概念视频
Liver Regeneration
4.2K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.2K
Liver Physiology
3.5K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
3.5K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
249
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
249
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
211
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
211

